BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ConjuGon, Inc. to Receive $2.4 Million for Defense R & D


10/24/2008 1:07:14 PM

Madison, WI—ConjuGon, Inc. will receive $2.4 million in federal funds to help continue development of its novel wound infection treatment product. ConjuGon’s work has life-saving promise for both military and public health care. The funds, requested by Congresswoman Tammy Baldwin (D-WI), were included in the Department of Defense Appropriations Bill for Fiscal Year 2009 which was signed into law on September 30th. Rep. Baldwin secured $1.2 million for the same project in Fiscal Year 2008.

“We are very excited to receive this federal funding. Military personnel and civilians often develop life-threatening bacterial infections following traumatic injury, and current antibiotics to fight these infections are becoming much less effective. Our aim is to deliver this novel antibacterial product to those in need as soon as possible, and these funds will help us reach that goal” said ConjuGon’s COO Steve Watt. “We would like to thank Congresswoman Baldwin for securing these funds, which support high-tech businesses and job creation in Wisconsin.”

“I’m delighted to help bring federal funds and national attention home to Wisconsin for this ground-breaking medical research. This kind of federal/local partnership creates good jobs along with revolutionary treatments that will save many, many lives,” said Rep. Baldwin.

ConjuGon is developing fundamentally new technologies to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon has two novel, biological products - one to prevent Catheter Associated Urinary Tract Infections and a second to treat antibiotic resistant wound infections. The company is located in the University Research Park in Madison, WI.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES